Mitochondrial DNA Variation Dictates Expressivity and Progression of Nuclear DNA Mutations Causing Cardiomyopathy

Area of Science:

• Genetics
• Mitochondrial Biology
• Cardiovascular Disease

Background:

• Nuclear gene mutations can cause metabolic and degenerative diseases with highly variable expressivity.
• Homozygous mutations in the adenine nucleotide translocator 1 gene (SLC25A4, ANT1) lead to cardiomyopathy of differing severity.
• This variability in disease severity has been observed to correlate with mitochondrial DNA (mtDNA) lineage.

Purpose of the Study:

• To investigate whether mitochondrial DNA (mtDNA) variants can modulate the expressivity of nuclear DNA (nDNA)-encoded diseases.
• To determine the impact of specific mtDNA variants on the phenotype of a nDNA-induced cardiomyopathy model.

Main Methods:

• Generation of a mouse model with the nDNA Slc25a4-/- null mutation.
• Introduction of homoplasmic mtDNA variants (ND6P25L or COIV421A) into the Slc25a4-/- background.
• Assessment of cardiomyopathy severity, mitochondrial function, oxidative stress, and lifespan.

Main Results:

• The Slc25a4-/- mutation combined with the ND6P25L mtDNA variant significantly exacerbated cardiomyopathy.
• The COIV421A mtDNA variant did not alter the cardiomyopathy phenotype in Slc25a4-/- mice.
• The adverse combination led to impaired mitochondrial complex I, increased oxidative damage, altered mitochondrial morphology, and shortened lifespan.

Conclusions:

• Mitochondrial DNA variants can act as significant modulators of autosomal diseases originating from nuclear gene mutations.
• Even mild mtDNA variants can have profound and differential effects on disease expressivity.
• This underscores the critical interplay between the nuclear and mitochondrial genomes in health and disease.